<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462358</url>
  </required_header>
  <id_info>
    <org_study_id>ARRAY-520-101</org_study_id>
    <nct_id>NCT00462358</nct_id>
  </id_info>
  <brief_title>A Study of ARRY-520 in Patients With Advanced Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Array Biopharma, now a wholly owned subsidiary of Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Array BioPharma</source>
  <brief_summary>
    <textblock>
      This is a Phase 1 study during which patients with advanced solid tumors will receive&#xD;
      investigational study drug ARRY-520.&#xD;
&#xD;
      This study has two parts. In the first part, patients with advanced solid tumors will receive&#xD;
      increasing doses of study drug, with or without granulocyte-colony stimulating factor (G-CSF)&#xD;
      support, in order to achieve the highest dose possible that will not cause unacceptable side&#xD;
      effects. Approximately 15 patients (per schedule) from the US will be enrolled in Part 1&#xD;
      (Completed).&#xD;
&#xD;
      In the second part of the study, patients will receive the best dose of study drug determined&#xD;
      from the first part of the study and will be followed to evaluate what side effects the study&#xD;
      drug causes and what effectiveness it has, if any, in treating the cancer. Approximately 15&#xD;
      patients from the US will be enrolled in Part 2 (Completed).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2007</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Establish the maximum tolerated dose (MTD) of study drug, with and without G-CSF.</measure>
    <time_frame>Part 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Characterize the safety profile of the study drug in terms of adverse events, clinical laboratory tests and electrocardiograms.</measure>
    <time_frame>Part 1 and Part 2</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetics of the study drug.</measure>
    <time_frame>Part 1 and Part 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the efficacy of the study drug in terms of tumor response.</measure>
    <time_frame>Part 1 and Part 2</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ARRY-520</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARRY-520 + G-CSF support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARRY-520, KSP(Eg5) inhibitor; intravenous</intervention_name>
    <description>Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.</description>
    <arm_group_label>ARRY-520</arm_group_label>
    <arm_group_label>ARRY-520 + G-CSF support</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous</intervention_name>
    <description>Part 1: standard of care; Part 2: standard of care.</description>
    <arm_group_label>ARRY-520 + G-CSF support</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological evidence of malignancy.&#xD;
&#xD;
          -  Advanced solid tumors that have recurred or progressed following standard&#xD;
             therapy(ies).&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.&#xD;
&#xD;
          -  Adequate hematology counts and serum chemistry values.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with an investigational product or device, or anti-neoplastic therapy (with&#xD;
             the exclusion of hormone therapy where the therapy will continue at a standard dose&#xD;
             throughout the study) within 28 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Major surgery within 28 days prior to the first dose of study drug.&#xD;
&#xD;
          -  Radiotherapy (RT) within 28 days prior to the first dose of study drug (except if&#xD;
             local RT to &lt;5% of the bone marrow).&#xD;
&#xD;
          -  Known positive serology for the human immunodeficiency virus (HIV), hepatitis C,&#xD;
             and/or active hepatitis B.&#xD;
&#xD;
          -  Additional criteria exist.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Marlene and Stewart Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University, Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>September 24, 2020</last_update_submitted>
  <last_update_submitted_qc>September 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Filanesib</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

